Wealth Enhancement Advisory Services LLC Raises Holdings in Aurinia Pharmaceuticals Inc $AUPH

Wealth Enhancement Advisory Services LLC boosted its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 20.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,989 shares of the biotechnology company’s stock after purchasing an additional 2,238 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Aurinia Pharmaceuticals were worth $110,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Nuveen LLC acquired a new position in shares of Aurinia Pharmaceuticals during the 1st quarter worth about $10,014,000. Jupiter Asset Management Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals in the 1st quarter valued at about $6,052,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Aurinia Pharmaceuticals by 34.1% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 746,229 shares of the biotechnology company’s stock valued at $6,000,000 after purchasing an additional 189,775 shares during the period. Trexquant Investment LP boosted its position in shares of Aurinia Pharmaceuticals by 58.5% in the 1st quarter. Trexquant Investment LP now owns 700,638 shares of the biotechnology company’s stock valued at $5,633,000 after purchasing an additional 258,620 shares during the period. Finally, AQR Capital Management LLC boosted its position in shares of Aurinia Pharmaceuticals by 8.7% in the 1st quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company’s stock valued at $4,048,000 after purchasing an additional 40,380 shares during the period. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Insider Activity

In other Aurinia Pharmaceuticals news, Director Kevin Tang bought 1,000,000 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was acquired at an average cost of $10.12 per share, with a total value of $10,120,000.00. Following the purchase, the director owned 11,029,500 shares in the company, valued at approximately $111,618,540. This represents a 9.97% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders purchased 1,300,000 shares of company stock worth $13,590,000. Corporate insiders own 12.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AUPH. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Royal Bank Of Canada upped their target price on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an “outperform” rating in a research report on Friday, August 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH stock opened at $11.27 on Monday. The company has a market cap of $1.48 billion, a price-to-earnings ratio of 26.21 and a beta of 1.25. The stock has a 50 day simple moving average of $12.06 and a 200-day simple moving average of $9.52. Aurinia Pharmaceuticals Inc has a 12-month low of $6.55 and a 12-month high of $13.54. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million for the quarter, compared to analysts’ expectations of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.